Prescription trends for Amarin’s Vascepa have grown meaningfully since before the REDUCE-IT study results were announced, Cantor Fitzgerald analyst Louise Chen tells investors in a research note, citing Symphony Health data. The analyst says the actual number of prescriptions for Vascepa is underrepresented by data sources such as Symphony as they count 30-day and 90-day as one prescription. Comparing the normalized and non-normalized prescription counts, Chen has seen a positive trend for Vascepa since June 30, 2017. The analyst’s relative percentages for normalized TRx and NRx data reported April 3 are showing increases of 138% and 163%, respectively. Chen keeps an Overweight rating on Amarin with a $35 price target. The stock closed Thursday up 24c to $6.05.